Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer.
Journal
Nature reviews. Urology
ISSN: 1759-4820
Titre abrégé: Nat Rev Urol
Pays: England
ID NLM: 101500082
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
accepted:
12
09
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
aheadofprint
Résumé
Early metastatic spread and clonal expansion of individual mutations result in a heterogeneous tumour landscape in metastatic urothelial cancer (mUC). Substantial molecular heterogeneity of common drug targets, such as membranous NECTIN4, FGFR3 mutations, PDL1 or immune phenotypes, has been documented between primary and metastatic tumours. However, translational and clinical studies frequently do not account for such heterogeneity and often investigate primary tumour samples that might not be representative in patients with mUC. We propose this as a potential factor for why many biomarkers for mUC have failed to be integrated into clinical practice. Fresh pre-treatment metastatic biopsies enable the capturing of prevailing tumour biology in real time. The characterization of metastatic tumour samples can improve response prediction to immunotherapy, the anti-NECTIN4 antibody-drug conjugate enfortumab vedotin and the FGFR inhibitor erdafitinib. Routine metastatic biopsy can thus improve the precision of identifying driver druggable alterations, thus improving treatment selection for patients with mUC.
Identifiants
pubmed: 39472646
doi: 10.1038/s41585-024-00951-2
pii: 10.1038/s41585-024-00951-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Nature Limited.
Références
Siefker-Radtke, A. O. Emerging therapies in the treatment of bladder cancer. J. Natl Compr. Cancer Netw. 21 (5.5), 1–3 (2023).
Cathomas, R. et al. The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur. Urol. 81, 95–103 (2021).
pubmed: 34742583
doi: 10.1016/j.eururo.2021.09.026
Vilaseca, A. et al. Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: phase 1 first-in-human study. J. Clin. Oncol. 41, TPS583 (2023).
doi: 10.1200/JCO.2023.41.6_suppl.TPS583
Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102–2114 (2021).
pubmed: 34077643
pmcid: 8215888
doi: 10.1056/NEJMoa2034442
Powles, T. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 383, 1218–1230 (2020).
pubmed: 32945632
doi: 10.1056/NEJMoa2002788
Rosenberg, J. E. et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin vs chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann. Oncol. 34, 1047–1054 (2023).
pubmed: 37678672
doi: 10.1016/j.annonc.2023.08.016
Van Der Heijden, M. S. et al. Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma. N. Engl. J. Med. 389, 1778–1789 (2023).
pubmed: 37870949
doi: 10.1056/NEJMoa2309863
Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875–888 (2024).
pubmed: 38446675
doi: 10.1056/NEJMoa2312117
Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol. 42, 47–58 (2024).
pubmed: 37870536
doi: 10.1200/JCO.23.02005
Wahida, A. et al. The coming decade in precision oncology: six riddles. Nat. Rev. Cancer 23, 43–54 (2023).
pubmed: 36434139
doi: 10.1038/s41568-022-00529-3
Loriot, Y. et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 389, 1961–1971 (2023).
pubmed: 37870920
doi: 10.1056/NEJMoa2308849
Clinton, T. N. et al. Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Rep. 41, 111859 (2022).
pubmed: 36543146
pmcid: 9882421
doi: 10.1016/j.celrep.2022.111859
Faltas, B. M. et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat. Genet. 48, 1490–1499 (2016).
pubmed: 27749842
pmcid: 5549141
doi: 10.1038/ng.3692
Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014).
pubmed: 24487277
pmcid: 4636053
doi: 10.1038/ng.2891
Bolenz, C. et al. Increasing biomarker guidance in the treatment of urothelial carcinoma: systematic review of international clinical trials. Urol. Int. 107, 480–488 (2023).
pubmed: 36630942
doi: 10.1159/000527879
Erlmeier, F. et al. Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition. Eur. Urol. 83, 133–142 (2022).
pubmed: 36372626
doi: 10.1016/j.eururo.2022.10.020
Amir, E. et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J. Clin. Oncol. 30, 587–592 (2012).
pubmed: 22124102
doi: 10.1200/JCO.2010.33.5232
Sharma, M., Gogia, A., Deo, S. S. V. & Mathur, S. Role of rebiopsy in metastatic breast cancer at progression. Curr. Probl. Cancer 43, 438–442 (2019).
pubmed: 30559028
doi: 10.1016/j.currproblcancer.2018.12.001
Klümper, N. et al. Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance. Clin. Cancer Res. 29, 1496–1505 (2022).
pmcid: 10102834
doi: 10.1158/1078-0432.CCR-22-1764
Hu, C. & Dignam, J. J. Biomarker-driven oncology clinical trials: key design elements, types, features, and practical considerations. JCO Precis. Oncol. 3, PO.19.00086 (2019).
pubmed: 32923854
pmcid: 7446374
LoRusso, P. M. & Freidlin, B. Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials. J. Natl Cancer Inst. 115, 122–124 (2022).
pmcid: 9905964
doi: 10.1093/jnci/djac212
Warrick, J. I. et al. Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants. Eur. Urol. 75, 18–22 (2019).
pubmed: 30266310
doi: 10.1016/j.eururo.2018.09.003
Choi, W. et al. Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset. Eur. Urol. 72, 354–365 (2017).
pubmed: 28365159
pmcid: 5764190
doi: 10.1016/j.eururo.2017.03.010
Lamy, P. et al. Paired exome analysis reveals clonal evolution and potential therapeutic targets in urothelial carcinoma. Cancer Res. 76, 5894–5906 (2016).
pubmed: 27488526
doi: 10.1158/0008-5472.CAN-16-0436
Thomsen, M. B. H. et al. Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma. Mol. Oncol. 10, 1450–1460 (2016).
pubmed: 27582092
pmcid: 5423216
doi: 10.1016/j.molonc.2016.08.003
Williams, M. J., Werner, B., Barnes, C. P., Graham, T. A. & Sottoriva, A. Identification of neutral tumor evolution across cancer types. Nat. Genet. 48, 238–244 (2016).
pubmed: 26780609
pmcid: 4934603
doi: 10.1038/ng.3489
Shi, M.-J. et al. APOBEC-mediated mutagenesis as a likely cause of FGFR3 S249C mutation over-representation in bladder cancer. Eur. Urol. 76, 9–13 (2019).
pubmed: 30975452
doi: 10.1016/j.eururo.2019.03.032
Shi, M.-J. et al. Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend’s Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated mutagenesis as, a likely cause of FGFR3 S249C mutation over-representation in bladder cancer. Eur. Urol. 77, e26–e27 (2020).
pubmed: 31493961
doi: 10.1016/j.eururo.2019.08.012
Meeks, J. J. et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat. Rev. Urol. 17, 259–270 (2020).
pubmed: 32235944
pmcid: 7968350
doi: 10.1038/s41585-020-0304-1
Liu, D. et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat. Commun. 8, 2193 (2017).
pubmed: 29259186
pmcid: 5736752
doi: 10.1038/s41467-017-02320-7
Swanton, C., McGranahan, N., Starrett, G. J. & Harris, R. S. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 5, 704–712 (2015).
pubmed: 26091828
pmcid: 4497973
doi: 10.1158/2159-8290.CD-15-0344
Li, Q. et al. ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer. Clin. Cancer Res. 25, 977–988 (2019).
pubmed: 29980530
doi: 10.1158/1078-0432.CCR-18-1001
Gil-Jimenez, A. et al. Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer. Eur. Urol. 83, 313–317 (2023).
pubmed: 35965206
doi: 10.1016/j.eururo.2022.07.023
Vendramin, R., Litchfield, K. & Swanton, C. Cancer evolution: darwin and beyond. EMBO J. 40, e108389 (2021).
pubmed: 34459009
pmcid: 8441388
doi: 10.15252/embj.2021108389
Nguyen, D. D. et al. Interplay mutagenesis extrachromosomal DNA shapes urothelial cancer evolution. Preprint at bioRxiv https://doi.org/10.1101/2023.05.07.538753 (2023).
Gerlinger, M. & Swanton, C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer 103, 1139–1143 (2010).
pubmed: 20877357
pmcid: 2967073
doi: 10.1038/sj.bjc.6605912
McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613–628 (2017).
pubmed: 28187284
doi: 10.1016/j.cell.2017.01.018
Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
pubmed: 28445112
doi: 10.1056/NEJMoa1616288
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
pubmed: 22397650
pmcid: 4878653
doi: 10.1056/NEJMoa1113205
Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).
pubmed: 35022204
doi: 10.1158/2159-8290.CD-21-1059
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
Facchinetti, F. et al. Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer. Cancer Discov. 13, 1998–2011 (2023).
pubmed: 37377403
pmcid: 10481128
doi: 10.1158/2159-8290.CD-22-1441
Wang, L. et al. A functional genetic screen identifies the phosphoinositide 3-kinase pathway as a determinant of resistance to fibroblast growth factor receptor inhibitors in FGFR mutant urothelial cell carcinoma. Eur. Urol. 71, 858–862 (2017).
pubmed: 28108151
doi: 10.1016/j.eururo.2017.01.021
Hosni, S. et al. Adipocyte precursor-derived NRG1 promotes resistance to FGFR inhibition in urothelial carcinoma. Cancer Res. 84, 725–740 (2024).
pubmed: 38175774
pmcid: 10911805
doi: 10.1158/0008-5472.CAN-23-1398
Agarwal, N. et al. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer 124, 2115–2124 (2018).
pubmed: 29517810
doi: 10.1002/cncr.31314
Barata, P. C. et al. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Ann. Oncol. 28, 2458–2463 (2017).
pubmed: 28945843
doi: 10.1093/annonc/mdx405
Wu, S. et al. Real world genomics in metastatic urothelial carcinoma (mUC). J. Clin. Oncol. 41, e16583 (2023).
doi: 10.1200/JCO.2023.41.16_suppl.e16583
Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152–165 (2014).
pubmed: 24525232
pmcid: 4011497
doi: 10.1016/j.ccr.2014.01.009
Damrauer, J. S. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl Acad. Sci. USA 111, 3110–3115 (2014).
pubmed: 24520177
pmcid: 3939870
doi: 10.1073/pnas.1318376111
The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014).
doi: 10.1038/nature12965
Seiler, R. et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur. Urol. 72, 544–554 (2017).
pubmed: 28390739
doi: 10.1016/j.eururo.2017.03.030
Sjödahl, G., Eriksson, P., Liedberg, F. & Höglund, M. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour‐cell phenotype classification. J. Pathol. 242, 113–125 (2017).
pubmed: 28195647
pmcid: 5413843
doi: 10.1002/path.4886
Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420–433 (2020).
pubmed: 31563503
doi: 10.1016/j.eururo.2019.09.006
Loriot, Y. et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 381, 338–348 (2019).
pubmed: 31340094
doi: 10.1056/NEJMoa1817323
Loriot, Y. et al. Phase 3 THOR study: results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt). J. Clin. Oncol. 41, LBA4619 (2023).
doi: 10.1200/JCO.2023.41.17_suppl.LBA4619
Dadhania, V. et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine 12, 105–117 (2016).
pubmed: 27612592
pmcid: 5078592
doi: 10.1016/j.ebiom.2016.08.036
Sjödahl, G. et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur. Urol. 81, 523–532 (2022).
pubmed: 34782206
doi: 10.1016/j.eururo.2021.10.035
Taber, A. et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat. Commun. 11, 4858 (2020).
pubmed: 32978382
pmcid: 7519650
doi: 10.1038/s41467-020-18640-0
Cox, A. et al. Molecular urothelial tumor cell subtypes remain stable during metastatic evolution. Eur. Urol. 85, 328–332 (2023).
pubmed: 37031005
doi: 10.1016/j.eururo.2023.03.020
Damrauer, J. S. et al. Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nat. Commun. 13, 6658 (2022).
pubmed: 36333289
pmcid: 9636269
doi: 10.1038/s41467-022-33980-9
Pfannstiel, C. et al. The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes. Cancer Immunol. Res. 7, 923–938 (2019).
pubmed: 30988029
doi: 10.1158/2326-6066.CIR-18-0758
Rose, T. L. et al. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br. J. Cancer 125, 1251–1260 (2021).
pubmed: 34294892
pmcid: 8548561
doi: 10.1038/s41416-021-01488-6
Necchi, A. et al. Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer. Eur. Urol. 77, 701–710 (2020).
pubmed: 32165065
doi: 10.1016/j.eururo.2020.02.028
Kim, J. et al. The Cancer Genome Atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability. Eur. Urol. 75, 961–964 (2019).
pubmed: 30851984
doi: 10.1016/j.eururo.2019.02.017
Griffin, J. et al. Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial. J. Pathol. Clin. Res. 10, e12363 (2024).
pmcid: 10835016
doi: 10.1002/2056-4538.12363
Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540–556.e25 (2017).
pubmed: 28988769
pmcid: 5687509
doi: 10.1016/j.cell.2017.09.007
Seiler, R. et al. Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Clin. Cancer Res. 25, 5082–5093 (2019).
pubmed: 30224344
doi: 10.1158/1078-0432.CCR-18-1106
Nakauma-González, J. A. et al. Comprehensive molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinoma. Eur. Urol. 81, 331–336 (2022).
pubmed: 35086719
doi: 10.1016/j.eururo.2022.01.026
Sjödahl, G. et al. Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer. Int. J. Cancer 154, 180–190 (2023).
pubmed: 37671617
doi: 10.1002/ijc.34715
Zhao, L. et al. Is GATA3 expression maintained in regional metastases?: A study of paired primary and metastatic urothelial carcinomas. Am. J. Surg. Pathol. 37, 1876–1881 (2013).
pubmed: 24121175
doi: 10.1097/PAS.0b013e31829e2525
Sjödahl, G. et al. Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases. Mod. Pathol. 31, 1869–1881 (2018).
pubmed: 29967424
doi: 10.1038/s41379-018-0096-5
Bontoux, C., Rialland, T., Cussenot, O. & Compérat, E. A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases. Virchows Arch. 478, 637–645 (2021).
pubmed: 33128085
doi: 10.1007/s00428-020-02951-0
Ohara, K. et al. The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis. Nat. Commun. 15, 2009 (2024).
pubmed: 38499531
pmcid: 10948878
doi: 10.1038/s41467-024-46320-w
Australian Pancreatic Cancer Genome Initiative et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
pmcid: 3776390
doi: 10.1038/nature12477
Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558–562 (2014).
pubmed: 25428503
doi: 10.1038/nature13904
Piombino, C. et al. Immunotherapy in urothelial cancer: current status and future directions. Expert Rev. Anticancer Ther. 23, 1141–1155 (2023).
pubmed: 37772970
doi: 10.1080/14737140.2023.2265572
[No authors listed.] Urothelial carcinoma trials get standing ovation. Cancer Discov. 13, 2496 (2023).
Zhu, X. & Koshkin, V. S. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer. Med 5, 106–108 (2023).
pubmed: 38128535
doi: 10.1016/j.medj.2023.11.010
Fenor De La Maza, M. D. et al. First line management of metastatic urothelial cancer: current and future perspectives after the EV-302 and CheckMate-901 studies. Clin. Genitourin. Cancer 22, 330–335 (2023).
pubmed: 38172023
doi: 10.1016/j.clgc.2023.12.001
Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819–1830 (2019).
pubmed: 30955977
doi: 10.1016/S0140-6736(18)32409-7
Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
pubmed: 31562797
doi: 10.1056/NEJMoa1910836
Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915–1928 (2019).
pubmed: 31679945
doi: 10.1016/S0140-6736(19)32591-7
Balar, A. V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 1483–1492 (2017).
pubmed: 28967485
doi: 10.1016/S1470-2045(17)30616-2
Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015–1026 (2017).
pubmed: 28212060
pmcid: 5635424
doi: 10.1056/NEJMoa1613683
Powles, T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391, 748–757 (2018).
pubmed: 29268948
doi: 10.1016/S0140-6736(17)33297-X
Galsky, M. D. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395, 1547–1557 (2020).
pubmed: 32416780
doi: 10.1016/S0140-6736(20)30230-0
Powles, T. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 931–945 (2021).
pubmed: 34051178
doi: 10.1016/S1470-2045(21)00152-2
Eckstein, M. et al. PD-L1 assessment in urothelial carcinoma: a practical approach. Ann. Transl. Med. 7, 690 (2019).
pubmed: 31930091
pmcid: 6944605
doi: 10.21037/atm.2019.10.24
Lopez-Beltran, A., López-Rios, F., Montironi, R., Wildsmith, S. & Eckstein, M. Immune checkpoint inhibitors in urothelial carcinoma: recommendations for practical approaches to PD-L1 and other potential predictive biomarker testing. Cancers 13, 1424 (2021).
pubmed: 33804698
pmcid: 8003923
doi: 10.3390/cancers13061424
Eckstein, M. et al. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur. J. Cancer 106, 234–243 (2019).
pubmed: 30528808
doi: 10.1016/j.ejca.2018.11.007
Tretiakova, M. et al. Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. Mod. Pathol. 31, 623–632 (2018).
pubmed: 29271413
doi: 10.1038/modpathol.2017.188
Schwamborn, K. et al. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Virchows Arch. 475, 599–608 (2019).
pubmed: 31267201
pmcid: 6861354
doi: 10.1007/s00428-019-02610-z
Hodgson, A. et al. PD-L1 immunohistochemistry assay concordance in urothelial carcinoma of the bladder and hypopharyngeal squamous cell carcinoma. Am. J. Surg. Pathol. 42, 1059–1066 (2018).
pubmed: 29750666
pmcid: 6750743
doi: 10.1097/PAS.0000000000001084
Downes, M. R., Slodkowska, E., Katabi, N., Jungbluth, A. A. & Xu, B. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma. Histopathology 76, 191–200 (2020).
pubmed: 31243779
doi: 10.1111/his.13946
Weyerer, V. et al. Integration of spatial PD-L1 expression with the tumor immune microenvironment outperforms standard PD-L1 scoring in outcome prediction of urothelial cancer patients. Cancers 13, 2327 (2021).
pubmed: 34066058
pmcid: 8150350
doi: 10.3390/cancers13102327
Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15, 25–41 (2015).
pubmed: 25533674
doi: 10.1038/nrc3817
Eckstein, M., Sikic, D., Strissel, P. L. & Erlmeier, F. Evolution of PD-1 and PD-L1 gene and protein expression in primary tumors and corresponding liver metastases of metastatic bladder cancer. Eur. Urol. 74, 527–529 (2018).
pubmed: 30007816
doi: 10.1016/j.eururo.2018.06.028
Rijnders, M. et al. Gene-expression-based T-cell-to-stroma enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer. Nat. Commun. 15, 1349 (2024).
pubmed: 38355607
pmcid: 10866910
doi: 10.1038/s41467-024-45714-0
Powles, T. et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N. Engl. J. Med. 384, 1125–1135 (2021).
pubmed: 33577729
pmcid: 8450892
doi: 10.1056/NEJMoa2035807
Azim, H. et al. Abstract B128: preclinical characterization of ETx-22, a next-generation antibody drug conjugate (ADC) targeting nectin-4. Mol. Cancer Ther. 22, B128 (2023).
doi: 10.1158/1535-7163.TARG-23-B128
Baldini, C. et al. BT8009-100: a phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC). J. Clin. Oncol. 41, 498 (2023).
doi: 10.1200/JCO.2023.41.6_suppl.498
Sheng, X. et al. Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials. J. Clin. Oncol. 42, 1391–1402 (2023).
pubmed: 37988648
doi: 10.1200/JCO.22.02912
Tagawa, S. T. et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J. Clin. Oncol. 35, 392–401 (2021).
Shimizu, T. et al. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody–drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J. Clin. Oncol. 41, 4678–4687 (2023).
pubmed: 37327461
pmcid: 10564307
doi: 10.1200/JCO.23.00059
Lisberg, A. et al. Datopotamab deruxtecan in locally advanced/metastatic urothelial cancer: preliminary results from the phase 1 TROPION-PanTumor01 study. J. Clin. Oncol. 42 (4_Suppl.), Abstr. 603 (2024).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04527991 (2024).
Dolgin, E. T-DXd granted first-ever tissue-agnostic ADC approval. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-NW2024-0024 (2024).
Loriot, Y. et al. Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression. J. Clin. Oncol. 41, 4579 (2023).
doi: 10.1200/JCO.2023.41.16_suppl.4579
Rosenberg, J. et al. EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J. Clin. Oncol. 38, 1041–1049 (2020).
pubmed: 32031899
pmcid: 7106979
doi: 10.1200/JCO.19.02044
Mosele, F. et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat. Med. 29, 2110–2120 (2023).
pubmed: 37488289
pmcid: 10427426
doi: 10.1038/s41591-023-02478-2
Ascione, L. et al. Predicting response to antibody drug conjugates: a focus on antigens’ targetability. Oncologist 28, 944–960 (2023).
pubmed: 37665782
pmcid: 10628585
doi: 10.1093/oncolo/oyad246
Chu, C. E. et al. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin. Cancer Res. 27, 5123–5130 (2021).
pubmed: 34108177
pmcid: 8634828
doi: 10.1158/1078-0432.CCR-20-4175
Challita-Eid, P. M. et al. Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 76, 3003–3013 (2016).
pubmed: 27013195
doi: 10.1158/0008-5472.CAN-15-1313
Hoffman-Censits, J. H. et al. Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes. Appl. Immunohistochem. Mol. Morphol. 29, 619–625 (2021).
pubmed: 33901032
pmcid: 8429050
doi: 10.1097/PAI.0000000000000938
Klümper, N. et al. NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer. J. Clin. Oncol. 42, 2446–2455 (2024).
pubmed: 38657187
doi: 10.1200/JCO.23.01983
Criscitiello, C., Morganti, S. & Curigliano, G. Antibody–drug conjugates in solid tumors: a look into novel targets. J. Hematol. Oncol. 14, 20 (2021).
pubmed: 33509252
pmcid: 7844898
doi: 10.1186/s13045-021-01035-z
Billerey, C. et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 158, 1955–1959 (2001).
pubmed: 11395371
pmcid: 1891972
doi: 10.1016/S0002-9440(10)64665-2
van Rhijn, B. W. G. et al. FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-FGFR3 treatment? Eur. Urol. 78, 682–687 (2020).
pubmed: 32682615
doi: 10.1016/j.eururo.2020.07.002
Tully, K. H. et al. Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer undergoing checkpoint inhibitor therapy. Urology 157, 93–101 (2021).
pubmed: 34153367
doi: 10.1016/j.urology.2021.05.055
Moss, T. J. et al. Comprehensive genomic characterization of upper tract urothelial carcinoma. Eur. Urol. 72, 641–649 (2017).
pubmed: 28601352
doi: 10.1016/j.eururo.2017.05.048
Su, X. et al. Comprehensive integrative profiling of upper tract urothelial carcinomas. Genome Biol. 22, 7 (2021).
pubmed: 33397444
pmcid: 7780630
doi: 10.1186/s13059-020-02230-w
Fujii, Y. et al. Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell 39, 793–809.e8 (2021).
pubmed: 34129823
pmcid: 9110171
doi: 10.1016/j.ccell.2021.05.008
Robinson, B. D. et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat. Commun. 10, 2977 (2019).
pubmed: 31278255
pmcid: 6611775
doi: 10.1038/s41467-019-10873-y
Gupta, S. et al. Quality improvement guidelines for percutaneous needle biopsy. J. Vasc. Interv. Radiol. 21, 969–975 (2010).
pubmed: 20304676
doi: 10.1016/j.jvir.2010.01.011
Solomon, S. B. et al. Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am. J. Roentgenol. 194, 266–269 (2010).
pubmed: 20028932
pmcid: 3676673
doi: 10.2214/AJR.09.2858
Patel, I. J. et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J. Vasc. Interv. Radiol. 23, 727–736 (2012).
pubmed: 22513394
doi: 10.1016/j.jvir.2012.02.012
Veltri, A., Bargellini, I., Giorgi, L., Almeida, P. A. M. S. & Akhan, O. CIRSE guidelines on percutaneous needle biopsy (PNB). Cardiovasc. Interv. Radiol. 40, 1501–1513 (2017).
doi: 10.1007/s00270-017-1658-5
Atwell, T. D. et al. Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin. AJR Am. J. Roentgenol. 194, 784–789 (2010).
pubmed: 20173160
doi: 10.2214/AJR.08.2122
Kasraeian, S., Allison, D. C., Ahlmann, E. R., Fedenko, A. N. & Menendez, L. R. A comparison of fine-needle aspiration, core biopsy, and surgical biopsy in the diagnosis of extremity soft tissue masses. Clin. Orthop. Relat. Res. 468, 2992–3002 (2010).
pubmed: 20512437
pmcid: 2947686
doi: 10.1007/s11999-010-1401-x
Rose, K. M. et al. Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease. Nat. Rev. Urol. 20, 406–419 (2023).
pubmed: 36977797
doi: 10.1038/s41585-023-00725-2
Merker, J. D. et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Arch. Pathol. Lab. Med. 142, 1242–1253 (2018).
pubmed: 29504834
doi: 10.5858/arpa.2018-0901-SA
Iravani, A., Violet, J., Azad, A. & Hofman, M. S. Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. Prostate Cancer Prostatic Dis. 23, 38–52 (2020).
pubmed: 31595044
doi: 10.1038/s41391-019-0174-x
Bakht, M. K. & Beltran, H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat. Rev. Urol. https://doi.org/10.1038/s41585-024-00900-z (2024).
Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).
pubmed: 34161051
pmcid: 8446332
doi: 10.1056/NEJMoa2107322
Kuo, P. et al. [
doi: 10.1200/JCO.2022.40.16_suppl.5002
Buteau, J. P. et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [
pubmed: 36261050
doi: 10.1016/S1470-2045(22)00605-2
Keyaerts, M. et al. Phase I study of
pubmed: 26449837
doi: 10.2967/jnumed.115.162024
Huang, W. et al. ImmunoPET imaging of Trop2 in patients with solid tumours. EMBO Mol. Med. 16, 1143–1161 (2024).
pubmed: 38565806
pmcid: 11099157
doi: 10.1038/s44321-024-00059-5
Powles, T. B. et al. LBA6 EV-302/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann. Oncol. 34, S1340 (2023).
doi: 10.1016/j.annonc.2023.10.106
Powles, T. et al. ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann. Oncol. 35, 485–490 (2024).
pubmed: 38490358
doi: 10.1016/j.annonc.2024.03.001
Miller, E. J. & Galsky, M. D. Precision medicine in urothelial carcinoma: current markers to guide treatment and promising future directions. Curr. Treat. Options Oncol. 24, 1870–1888 (2023).
pubmed: 38085403
doi: 10.1007/s11864-023-01151-7